RIGL Rigel Pharmaceuticals Inc.

1.64
+0.04  (+2%)
Previous Close 1.6
Open 1.61
Price To Book 3.48
Market Cap 274,040,787
Shares 167,609,044
Volume 1,735,063
Short Ratio
Av. Daily Volume 1,517,178
Stock charts supplied by TradingView

NewsSee all news

  1. Rigel Secures Credit Facility for Up to $60 Million

    SOUTH SAN FRANCISCO, Oct. 2, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has entered into a $60 million term loan credit facility with MidCap Financial ("MidCap"). At

  2. Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia

    SOUTH SAN FRANCISCO, Calif., Sept. 23, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that its collaboration partner, Kissei Pharmaceuticals Co., Ltd. ("Kissei"), has initiated a

  3. Rigel's CEO to Participate in Panel Discussion at Citi's 14th Annual Biotech Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data released April 3, 2018. Primary endpoint not met.
Fostamatinib
IgA nephropathy
Phase 2 trial did not meet endpoints
R348
Chronic dry eye disease - as a result of patients with acute or chronic graft vs. host disease (GvHD)
Approved April 17, 2018.
Tavalissetm (Fostamatinib)
Immune Thrombocytopenic Purpura (ITP)
Phase 3 data due mid-2021.
Fostamatinib
Autoimmune hemolytic anemia (AIHA)
Phase 1 initial data due 2H 2019.
R835
Autoimmune and inflammatory diseases

Latest News

  1. Rigel Secures Credit Facility for Up to $60 Million

    SOUTH SAN FRANCISCO, Oct. 2, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has entered into a $60 million term loan credit facility with MidCap Financial ("MidCap"). At

  2. Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia

    SOUTH SAN FRANCISCO, Calif., Sept. 23, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that its collaboration partner, Kissei Pharmaceuticals Co., Ltd. ("Kissei"), has initiated a

  3. Rigel's CEO to Participate in Panel Discussion at Citi's 14th Annual Biotech Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to